Production & Sales

Ferring launches Nocdurna in US to treat nocturia due to NP

Ferring Pharmaceuticals has announced the US launch of NOCDURNA (desmopressin acetate), a sublingual tablet indicated for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken more than two times per night to void.

AstraZeneca to sell asthma and rhinitis drug rights to Covis Pharma for $350m

AstraZeneca has agreed to offload its rights to asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Covis Pharma for $350m.

Quotient Sciences extends formulation and manufacturing operations in UK

Quotient Sciences, a global pharmaceutical development, clinical pharmacology and clinical and commercial manufacturing organization, has significantly expanded its formulation development and clinical trial manufacturing operations at its Reading facility, UK.

Janssen recalls Ortho-Novum tablets over incorrect Veridate dispenser instructions

Janssen Pharmaceuticals is voluntary recalling one lot of Ortho-Novum 1/35 (norethindrone/ethinyl estradiol) tablets and two lots of Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol) tablets to the pharmacy level.

GW announces US launch of cannabinoid medicine for seizures

GW Pharmaceuticals, along with its US subsidiary Greenwich Biosciences, has launched EPIDIOLEX (cannabidiol) oral solution CV in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older.

Grünenthal to buy AstraZeneca’s European rights to two drugs for $922m

German pharma company Grünenthal has agreed to acquire certain rights to AstraZeneca’s Nexium (esomeprazole) and Vimovo (naproxen/esomeprazole) for a sum of up to $922m.

EQT offers to buy Karo Pharma for $654m

Private equity firm EQT has proposed to acquire 100% of Karo Pharma, a Swedish pharma company, for around SEK5.97bn ($654m).

Mayne Pharma acquires rights for psoriasis corticosteroid halobetasol foam

Mayne Pharma has acquired the US and Australian rights to halobetasol foam 0.05% for a sum of up to $32m, which includes contingent payments of up to $17m based on commercial milestones and other factors.

Cipher launches Brinavess antiarrhythmic drug in Canada

Cipher Pharmaceuticals has announced the Canadian launch of Brinavess (vernakalant hydrochloride) for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm (SR) for non-surgery patients with duration of AF less than seven days and post-cardiac surgery patients with duration of AF less than three days.